Otero Jose Manuel 4
4 · Lexeo Therapeutics, Inc. · Filed Mar 17, 2026
Research Summary
AI-generated summary of this filing
Lexeo Therapeutics COO Jose Manuel Otero Receives 5,930-Share Award
What Happened
- Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics (LXEO), acquired 5,930 shares of company common stock on 2026-03-13 at $2.64 per share, for a total value of approximately $15,679. The filing classifies this as an award/acquisition under the company's 2023 Employee Stock Purchase Plan (ESPP).
Key Details
- Transaction date: 2026-03-13; Filing date: 2026-03-17 (filed within the standard reporting window).
- Price: $2.64 per share; Shares acquired: 5,930; Total value: ~$15,679.
- Footnote F1: Reported voluntarily under the 2023 ESPP; transaction is exempt under Rule 16b-3(c) and 16b-3(d).
- Footnote F2: Filing notes holdings include 104,216 restricted stock units (RSUs).
- Filing type: Form 4 (insider report). No late-filing flag was indicated.
Context
- This was an acquisition through the company ESPP (an employee purchase), which is a routine way employees obtain stock and is exempt under certain Section 16 rules. The dollar amount is modest relative to typical insider trades; factual reporting of this purchase does not by itself imply management sentiment.
Insider Transaction Report
Form 4
Otero Jose Manuel
Chief Operating Officer
Transactions
- Award
Common Stock
[F1][F2]2026-03-13$2.64/sh+5,930$15,679→ 131,390 total
Footnotes (2)
- [F1]The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
- [F2]Includes 104,216 restricted stock units.
Signature
/s/ Youjin Choi, Attorney-in-Fact|2026-03-17